Suchergebnisse - "Dhall, Rohit"

PubPharm (59)

1

Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless) : a phase 3, randomised, double-blind, double-dummy, multicentre trial

enthalten in: The Lancet. Neurology | 2024

von Espay, A. | Stocchi, F. | Pahwa, R. | +87

2

A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease

enthalten in: Movement disorders : official journal of the Movement Disorder Society | 2024

von Olanow, C. | Hauser, R. | Burdick, D. | +8

3

Safety and Efficacy of IPX203 in Parkinson's Disease : The RISE-PD Open-Label Extension Study

enthalten in: Movement disorders : official journal of the Movement Disorder Society | 2024

von Espay, A. | Hauser, R. | Dhall, R. | +6

4

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease : a randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Neurology | 2024

von McGarry, A. | Rosanbalm, S. | Leinonen, M. | +25

CommentIn: Lancet Neurol. 2024 Jan;23(1):2-3. - PMID 38101888

5

A Randomized Phase 3 Study Comparing P2B001 to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early Parkinson's Disease

enthalten in: Movement Disorders | 2024

von Olanow, C. | Hauser, R. | Burdick, D. | +7

6

Safety and Efficacy of IPX203 in Parkinson's Disease : The RISE‐PD Open‐Label Extension Study

enthalten in: Movement Disorders | 2024

von Espay, A. | Hauser, R. | Dhall, R. | +6

7

Impedance trend from a symptomatic perielectrode cystic cavity following deep brain stimulation : illustrative case

enthalten in: Journal of neurosurgery. Case lessons | 2023

von Elberson, B. | Scott, H. | Dhall, R. | +1

8

Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD) : a phase 3, randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Neurology | 2023

von Furr Stimming, E. | Claassen, D. | Kayson, E. | +96

CommentIn: Lancet Neurol. 2023 Jun;22(6):459-460. - PMID 37210087

9

Improving levodopa delivery : IPX203, a novel extended-release carbidopa-levodopa formulation

enthalten in: Clinical parkinsonism & related disorders | 2023

von LeWitt, P. | Ellenbogen, A. | Burdick, D. | +5

10

The Safety of Deutetrabenazine for Chorea in Huntington Disease : An Open-Label Extension Study

enthalten in: CNS drugs | 2022

von Frank, S. | Testa, C. | Edmondson, M. | +105

1
2
3
4
5
6
Nächster »
[6]